Dr. Sarah Chen’s hands trembled as she closed another notebook from a failed experiment. Five years. Seventeen drug candidates. Zero successes. The cancer protein she was hunting—TIM-3—mocked her from every failed assay. Pharmaceutical giants had thrown billions at it. The target was “undruggable.” Not because the biology was wrong. TIM-3 absolutely drove tumor resistance. But the protein’s binding pocket was too shallow, too flexible for traditional drug molecules to grip. It was like trying to grab smoke.

Sarah represented millions of researchers facing an uncomfortable truth: 80% of disease-causing proteins in the human body can’t be targeted with current technologies because their molecules won’t bind to our tools.

Then, on a Tuesday morning in May 2024, everything changed. Her colleague submitted TIM-3’s genetic sequence to a new system called AlphaFold 3. No experimental data. No protein crystals. Just the genetic code. Seven seconds later, they had atomic-resolution predictions of exactly how potential drug molecules would bind. Within weeks, they synthesized three candidates. Within months, they had lead compounds showing promise. The “undruggable” target wasn’t undruggable anymore.

This transformation is why Isomorphic Labs, a London-based AI drug discovery company, has won the 2026 Global Recognition Award for reimagining pharmaceutical development through artificial intelligence that not only accelerates existing processes but fundamentally redefines what’s possible in treating human disease. Founded in 2021 by Sir Demis Hassabis (2024 Nobel Prize in Chemistry laureate, Google DeepMind co-founder/CEO), Isomorphic achieved $600+ million in funding, secured partnerships with Eli Lilly, Novartis, and Johnson & Johnson worth nearly $3 billion combined, and developed AlphaFold 3—the first AI system to surpass physics-based tools for biomolecular structure prediction.

Technical Innovation and Architecture

Isomorphic’s breakthrough builds upon AlphaFold 3, announced in May 2024 as the AI model that predicts the structure and interactions of virtually all biomolecules with unprecedented accuracy. While AlphaFold 2 solved the 50-year-old protein structure prediction problem—earning Hassabis and DeepMind researcher John Jumper the 2024 Nobel Prize—AlphaFold 3 expands capabilities to predict how proteins interact with DNA, RNA, small molecules, antibodies, peptides, and ions. The model achieves 50% improvement over existing methods, doubling accuracy for some critical interactions.

For drug discovery specifically, AlphaFold 3 is 50% more accurate than traditional methods for predicting protein-ligand binding—without requiring any structural information input. This marks the first AI system to surpass physics-based tools, a watershed moment. The proprietary drug design engine integrates specialized models for peptides, molecular glues, and antibodies, drawing on the global Protein Data Bank, UK Biobank genetics from 500,000+ participants, and partner collaboration data.

Scientists at Isomorphic create and test hypotheses at the atomic level, producing structure predictions within seconds, rather than months to years for experimental methods. The platform eliminates time-consuming preclinical trial-and-error, addressing the brutal economics of pharmaceutical development: $2.6 billion and 10-15 years per approved drug, with 90%+ clinical failure rates. When Isomorphic examined TIM-3 for cancer immunotherapy, they used structure-based predictions to guide compound design against targets previously considered undruggable. Researchers have already used AlphaFold to design and synthesize potential drugs for hepatocellular carcinoma, while DeepMind collaborates with the Drugs for Neglected Diseases initiative on therapeutics for Chagas and Leishmaniasis.

Market Strategy and Leadership

Demis Hassabis founded Isomorphic in November 2021 with a vision that sounded like science fiction: “Solve all disease.” Not eliminating illness, but building systematic, repeatable AI-powered processes for discovering therapeutics as needs arise. His credentials are unmatched: co-founding DeepMind in 2010 (Google acquisition 2014), achieving AlphaGo’s victory over the world champion Go player in 2016, AlphaFold 2 solving protein structure prediction in 2020, and now Gemini competing with OpenAI’s GPT models.

The founding vision emerged directly from AlphaFold 2’s success: “What if you could turn AlphaFold into a full-fledged drug-design engine?” His 2024 Nobel Prize in Chemistry with Jumper represents rare recognition of AI/computational work with chemistry’s highest honor—ultimately validating it.

When Eli Lilly’s executives first heard Isomorphic’s pitch in late 2023, they were skeptical. The pharmaceutical industry had seen countless AI promises fail. But Isomorphic wasn’t typical. They had a Nobel Prize-winning founder whose previous breakthrough was being used by 2 million researchers in 190 countries, technology that demonstrably worked, Alphabet’s unlimited computational resources, and humility about limitations. Eli Lilly didn’t just license the technology—they bet their future on it. In January 2024, they signed a multi-target partnership worth over $1.5 billion in potential payments. That same week, Novartis did the same. Two years later, Johnson & Johnson joined them.

Three of the world’s largest pharmaceutical companies committed nearly $3 billion to a company barely three years old. Why? Because if Isomorphic’s AI could genuinely access 80% of disease-causing proteins currently beyond reach, whoever partnered first would own the next generation of medicine.

The March 2025 $600 million funding round, led by Thrive Capital with participation from GV and Alphabet, demonstrated that “investor interest in AI is still strong—especially if the company is backed by Nobel Prize-winning science.” Hassabis emphasizes the vision: “A biotech startup might do one or two drugs its entire corporate life. But we’re trying to build a system to do maybe dozens of drugs each year.“

Industry Impact and Future Vision

The numbers are staggering: $600 million raised, $3 billion in partnerships, 50% accuracy improvements, and predictions in seconds. But numbers don’t capture what this means for Ana, a mother in rural Brazil watching her daughter waste away from Chagas disease. This neglected tropical illness kills thousands annually but receives almost no pharmaceutical investment because patients are poor. Numbers don’t explain what it means to Marcus, diagnosed with a rare cancer driven by a protein scientists couldn’t drug.

Isomorphic’s technology enables the Drugs for Neglected Diseases initiative (DNDi) to design therapeutics for Chagas and Leishmaniasis—diseases Big Pharma ignored because they weren’t profitable. Now they might be treatable because AI makes discovery affordable. It allows researchers to design drugs targeting proteins previously considered undruggable in hepatocellular carcinoma. Some AI-designed compounds have already been synthesized and are being tested.

The open-access approach to AlphaFold 2—enabling 2+ million researchers from 190 countries to use the technology freely—accelerated scientific progress worldwide, in contrast to the pharmaceutical industry’s typical IP protectionism. The October 2024 Nobel Prize validation, combined with geographic expansion across London headquarters, Lausanne, Switzerland, and Cambridge, Massachusetts, positions Isomorphic to advance wholly owned compounds toward clinical trials.

In Isomorphic’s offices, scientists work toward something unprecedented: a “virtual cell” that can predict exactly what happens when you intervene in biological systems. Imagine uploading a disease mechanism, simulating thousands of potential drugs, predicting effects with atomic precision, and identifying optimal candidates—all before synthesizing a single compound. That’s not science fiction. That’s Isomorphic’s roadmap.

For investors seeking ventures where returns come with returns to humanity, Isomorphic represents the blueprint. For pharmaceutical companies watching rivals partner: the window is closing. For patients like Ana and Marcus: when “undruggable” becomes a relic of the past, when systematic AI-powered discovery makes therapeutics faster and cheaper—the future arrives for everyone.

This recognition isn’t for incremental improvement. It’s for fundamentally reimagining what’s possible when artificial intelligence meets human biology. It’s for taking a 50-year-old “impossible” problem and making it routine. It’s for convincing the world’s most conservative industry to wager $3 billion on a new paradigm. It’s for pursuing profit and purpose simultaneously—partnering with Eli Lilly while helping DNDi design drugs no one else will touch.